Johnson & Johnson Gain (Loss) on Sale of Assets and Asset Impairment Charges increased by 5800.0% to $57.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 2750.0%, from $2.00M to $57.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Consistent losses or impairments suggest inefficient asset management or poor strategic planning regarding asset life cycles.
This is a combined line item representing the net impact of asset sales and impairment charges on the income statement....
Common in large, diversified conglomerates that frequently buy and sell business units or production facilities.
cf_jnj_gain_loss_on_sale_and_impairment| Q2 '21 | Q2 '22 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $580.00M | $168.00M | $8.00M | $0.00 | $223.00M | $2.00M | $1.00M | $75.00M | -$1.00M | $57.00M |
| QoQ Change | — | -71.0% | -95.2% | -100.0% | — | -99.1% | -50.0% | >999% | -101.3% | >999% |
| YoY Change | — | -71.0% | -95.2% | — | >999% | — | — | — | -100.4% | >999% |
We use cookies for analytics. See our Privacy and Cookie Policy.